BPC September 06 update

ENDP shares rally on regulatory submission +48%

Price and Volume Movers

Endo International plc (NASDAQ: ENDP) shares closed up 48% to $3.48. The company announced it has submitted a Biologics License Application (BLA) to the FDA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Turning Point Therapeutics, Inc. (Nasdaq: TPTX) shares closed down 9% to $42.75 following the pricing of its public offering of 4.5m shares at a price of $45 per share for gross proceeds of $202.5m

Mallinckrodt Plc (NYSE: MNK) announced that it has reached a settlement in principle regarding allegations of its role in the U.S. opioid epidemic. If the settlement is confirmed, the company will pay a total sum of $24m in cash and donate $6m in generic products, including addiction treatment products, avoiding facing trial over the lawsuit. Shares closed up 18% to $1.87.

Avid Bioservices (NASDAQ: CDMO) shares closed down 23% to $5.45 following the release of its latest quarterly earnings.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

BeyondSpring Inc. (BYSI): $21.65; +19%.

Autolus Therapeutics Plc (AUTL): $14.09; +18%.

Applied Genetic Technologies Corporation (AGTC): $3.76; +18%.

Neon Therapeutics, Inc. (NTGN): $3.33; +14%.

Ovid Therapeutics Inc. (OVID): $2.17; +14%.

DECLINERS:

PhaseBio Pharmaceuticals, Inc. (PHAS): $5.05; -19%.

NextCure, Inc. (NXTC): $34.34; -17%.

Plus Therapeutics, Inc. (PSTV): $10.05; -15%.

Checkpoint Therapeutics, Inc. (CKPT): $2.70; -12%.

Mersana Therapeutics, Inc. (MRSN): $2.10; -9%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

BSTC – BioSpecifics Technologies Corp
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)

BLA Filing BLA filing announced September 6, 2019.
$431.7 million

OGEN – Oragenics Inc.
AG013
Oral mucositis (OM)

Phase 2 Phase 2 top-line data due 1Q 2020.
$26.3 million